Shanghai Pharma's controlling shareholder to boost H-share stake

Shanghai Pharmaceuticals Holding Company Limited announced that its controlling shareholder, Shanghai Industrial Investment Co., Ltd., through its wholly-owned subsidiary SIIC International Investment Co., Ltd., plans to increase its stake in the company. SIIC International Investment Co., Ltd. currently holds 300,538,000 H shares, representing 8.104% of the total share capital.

The planned increase involves acquiring 55 million to 74 million additional H shares, which equates to 1.5% to 2% of the total share capital. This will be executed through concentrated bidding on the Hong Kong Stock Exchange system over 12 months, starting September 15, 2025, and ending September 14, 2026. The funding will come from SIIC International Investment Co., Ltd.'s own capital, with no fixed price range set.

SIIC International Investment Co., Ltd. has pledged not to reduce its holdings in Shanghai Pharmaceuticals for six months following the completion of the share increase. The company confirmed this plan is based on confidence in its future stable development and long-term investment value.